Novartis Terminates Clinical Development of Fevipiprant (AW039) in P-III LUSTER Studies for Patients with Uncontrolled GINA 4/5 Asthma

 Novartis Terminates Clinical Development of Fevipiprant (AW039) in P-III LUSTER Studies for Patients with Uncontrolled GINA 4/5 Asthma

Novartis Terminates Clinical Development of Fevipiprant (AW039) in P-III LUSTER Studies for Patients with Uncontrolled GINA 4/5 Asthma

Shots:

  • The P-III LUSTER-1 & 2 studies involve assessing of Fevipiprant (150/ 450mg) vs PBO in 894 & 877 patients aged ≥12yrs. in a ratio (1:1:1) with moderate-severe asthma, receiving GINA 4 and 5 SoC asthma therapy for 52wks. respectively
  • The pooled analysis of P-III LUSTER 1 & 2 study did not support the further development of Fevipiprant for asthma as a primary indication, but it was well tolerated with AEs balanced across treatments groups
  • Fevipiprant (qd) is an investigational, steroid-free therapy, act by blocking the DP2 pathway. Additionally, Novartis continues to invest in respiratory therapies with its respiratory portfolio including Xolair, Ultibro Breezhaler, QVM149

Click here to­ read full press release/ article | Ref: Novartis | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post